Results Wire: US FDA Advisory Committee Gives Input on BioMarin’s Drisapersen for Duchenne Muscular Dystrophy – NOV 24, 2015 (PCNS)

On Tuesday, November 24, 2015, the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) gave input on New Drug Application (NDA) 20631 by BioMarin Pharmaceutical, Inc. (BioMarin) for drisapersen solution for injection, for the treatment of patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping as determined by genetic testing.

See the SAC Tracker report